Scaling Parenteral Drug Delivery: Why Next-Gen Biologics Demand a Specialized Device CDMO
As biopharmaceutical pipelines shift toward self-administered biologics, high-concentration formulations, and GLP-1 biosimilars, the boundary between drug product and drug delivery device has disappeared. Modern therapies require parenteral systems engineered for precision, safety, and rapid market deployment. At MayMag Biologics , we bridge the gap between complex formulation physics and commercial-scale device manufacturing. Partnering with leading pharmaceutical innovators, we offer end-to-end device development, cleanroom assembly, and fill-finish continuity under one certified quality management system. Core Device Capabilities & Engineering Solutions 1. Custom Pen Injector Device Developer Off-the-shelf injection systems rarely accommodate the unique viscosity profiles and dosing precision required by novel biologic compounds. As a Custom Pen Injector Device Developer , MayMag Biologics customizes multi-dose and single-dose pen platforms tailored to your exact pay...